| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ashima Saxena, James M Fedorko, C R Vinayaka, Rohit Medhekar, Zoran Radić, Palmer Taylor, Oksana Lockridge, Bhupendra P Docto. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept) to cholinesterases. European journal of biochemistry. vol 270. issue 22. 2004-02-06. PMID:14622273. |
e2020 (r,s)-1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methyl)piperidine hydrochloride is a piperidine-based acetylcholinesterase (ache) inhibitor that was approved for the treatment of alzheimer's disease in the united states. |
2004-02-06 |
2023-08-12 |
mouse |
| Alan M Palme. Cholinergic therapies for Alzheimer's disease: progress and prospects. Current opinion in investigational drugs (London, England : 2000). vol 4. issue 7. 2004-01-22. PMID:14619403. |
cholinomimetic drugs are now available to treat the cognitive impairments associated with alzheimer's disease (ad), although evidence indicates that the effects of acetylcholinesterase (ache) inhibitors on measures of cognitive function may be secondary to an action on attentional mechanisms. |
2004-01-22 |
2023-08-12 |
Not clear |
| Yeon-Kye Kim, Byung-Soo Koo, Dae-Jong Gong, Young-Choon Lee, Jeong-Heon Ko, Cheorl-Ho Ki. Comparative effect of Prunus persica L. BATSCH-water extract and tacrine (9-amino-1,2,3,4-tetrahydroacridine hydrochloride) on concentration of extracellular acetylcholine in the rat hippocampus. Journal of ethnopharmacology. vol 87. issue 2-3. 2003-12-29. PMID:12860300. |
in this study, the effects of oral administration of ppe on the extracellular acetylcholine concentration in the hippocampus of rats were evaluated, and compared to that of tacrine (9-amino-1,2,3,4-tetrahydroacridine hydrochloride), a well-known and centrally acting acetylcholinesterase (ache) inhibitor, which had been developed for the treatment of alzheimer's disease. |
2003-12-29 |
2023-08-12 |
rat |
| Narihiro Toda, Keiko Tago, Shinji Marumoto, Kazuko Takami, Mayuko Ori, Naho Yamada, Kazuo Koyama, Shunji Naruto, Kazumi Abe, Reina Yamazaki, Takao Hara, Atsushi Aoyagi, Yasuyuki Abe, Tsugio Kaneko, Hiroshi Koge. Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorganic & medicinal chemistry. vol 11. issue 9. 2003-12-12. PMID:12670645. |
we have designed and synthesized a dual inhibitor of acetylcholinesterase (ache) and serotonin transporter (sert) as a novel class of treatment drugs for alzheimer's disease on the basis of a hypothetical model of the ache active site. |
2003-12-12 |
2023-08-12 |
mouse |
| Min Wu, Samuel S Newton, Joshua B Atkins, Changqing Xu, Ronald S Duman, Meenakshi Alrej. Acetylcholinesterase inhibitors activate septohippocampal GABAergic neurons via muscarinic but not nicotinic receptors. The Journal of pharmacology and experimental therapeutics. vol 307. issue 2. 2003-12-10. PMID:12966162. |
acetylcholinesterase (ache) inhibitors, which increase synaptic levels of available acetylcholine (ach) by preventing its degradation, are the most extensively prescribed drugs for the treatment of alzheimer's disease. |
2003-12-10 |
2023-08-12 |
rat |
| Marcelo A Chacón, Ariel E Reyes, Nibaldo C Inestros. Acetylcholinesterase induces neuronal cell loss, astrocyte hypertrophy and behavioral deficits in mammalian hippocampus. Journal of neurochemistry. vol 87. issue 1. 2003-11-12. PMID:12969266. |
moreover, ache is present in senile plaques in alzheimer's disease (ad) brains. |
2003-11-12 |
2023-08-12 |
rat |
| T Rees, P I Hammond, H Soreq, S Younkin, S Brimijoi. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiology of aging. vol 24. issue 6. 2003-10-29. PMID:12927760. |
studies in vitro have suggested that acetylcholinesterase (ache) may interact with beta-amyloid to promote deposition of amyloid plaques in the brain of patients with alzheimer's disease. |
2003-10-29 |
2023-08-12 |
mouse |
| T Rees, P I Hammond, H Soreq, S Younkin, S Brimijoi. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiology of aging. vol 24. issue 6. 2003-10-29. PMID:12927760. |
these histological and biochemical results support the conclusion that ache may play a role in pathogenesis of alzheimer's disease |
2003-10-29 |
2023-08-12 |
mouse |
| Matthew G Cottingham, Jan L A Voskuil, David J T Vau. The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers. Biochemistry. vol 42. issue 36. 2003-10-14. PMID:12962511. |
a 14-residue fragment of the c-terminal oligomerization domain, or t-peptide, of human acetylcholinesterase (ache) shares sequence homology with the amyloid-beta peptide implicated in alzheimer's disease and can spontaneously self-assemble into classical amyloid fibrils under physiological conditions [greenfield, s. a., and vaux, d. j. |
2003-10-14 |
2023-08-12 |
human |
| Yuki Takada, Atsushi Yonezawa, Toshiaki Kume, Hiroshi Katsuki, Shuji Kaneko, Hachiro Sugimoto, Akinori Akaik. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. The Journal of pharmacology and experimental therapeutics. vol 306. issue 2. 2003-08-28. PMID:12734391. |
donepezil is a potent and selective acetylcholinesterase (ache) inhibitor developed for the treatment of alzheimer's disease. |
2003-08-28 |
2023-08-12 |
rat |
| Sultan Darvesh, Ryan Walsh, Rohit Kumar, Angela Caines, Sheila Roberts, David Magee, Kenneth Rockwood, Earl Marti. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer disease and associated disorders. vol 17. issue 2. 2003-08-05. PMID:12794390. |
given that drugs that are currently in use for the treatment of alzheimer disease inhibit both ache and buche, the development of drugs targeted toward the exclusive inhibition of one or the other cholinesterase may be important for understanding the relative importance of inhibition of buche and ache in the treatment of this disease. |
2003-08-05 |
2023-08-12 |
human |
| Tina M Rees, Stephen Brimijoi. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs of today (Barcelona, Spain : 1998). vol 39. issue 1. 2003-08-01. PMID:12669110. |
treatment of alzheimer's disease has been dominated by the use of acetylcholinesterase (ache) inhibitors. |
2003-08-01 |
2023-08-12 |
Not clear |
| Tina M Rees, Stephen Brimijoi. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs of today (Barcelona, Spain : 1998). vol 39. issue 1. 2003-08-01. PMID:12669110. |
recently, however, ache itself has been implicated in the pathogenesis of alzheimer's disease. |
2003-08-01 |
2023-08-12 |
Not clear |
| Tina M Rees, Stephen Brimijoi. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs of today (Barcelona, Spain : 1998). vol 39. issue 1. 2003-08-01. PMID:12669110. |
it therefore seems likely that new ache inhibitors, which capitalize on all these strengths would be excellent candidates for future alzheimer's disease therapy. |
2003-08-01 |
2023-08-12 |
Not clear |
| Laura A Volpicelli-Daley, Ellen G Duysen, Oksana Lockridge, Allan I Leve. Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice. Annals of neurology. vol 53. issue 6. 2003-07-09. PMID:12783426. |
a primary therapeutic strategy for alzheimer's disease includes acetylcholinesterase (ache) inhibitors with the goal of enhancing cholinergic transmission. |
2003-07-09 |
2023-08-12 |
mouse |
| Laura A Volpicelli-Daley, Ellen G Duysen, Oksana Lockridge, Allan I Leve. Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice. Annals of neurology. vol 53. issue 6. 2003-07-09. PMID:12783426. |
the alterations of machrs in ache -/- mice suggest that machr downregulation may contribute to the limited efficacy of ache inhibitors in alzheimer's disease treatment. |
2003-07-09 |
2023-08-12 |
mouse |
| Nigel H Greig, Debomoy K Lahiri, Kumar Sambamurt. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. International psychogeriatrics. vol 14 Suppl 1. 2003-07-03. PMID:12636181. |
however, buche activity progressively increases in patients with alzheimer's disease (ad), while ache activity remains unchanged or declines. |
2003-07-03 |
2023-08-12 |
Not clear |
| Stephen M Stahl, Jeffrey S Markowitz, Elane M Gutterman, George Papadopoulo. Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. The Journal of clinical psychiatry. vol 64. issue 4. 2003-07-01. PMID:12716251. |
in clinical trials, sleep problems have been identified as side effects of donepezil, an acetylcholinesterase (ache)-inhibiting medication for the treatment of alzheimer's disease (ad). |
2003-07-01 |
2023-08-12 |
Not clear |
| Sultan Darvesh, Ryan Walsh, Earl Marti. Enantiomer effects of huperzine A on the aryl acylamidase activity of human cholinesterases. Cellular and molecular neurobiology. vol 23. issue 1. 2003-05-20. PMID:12701885. |
(-) huperzine a is an inhibitor of ache and is being considered for the treatment of alzheimer's disease. |
2003-05-20 |
2023-08-12 |
human |
| Javier Sáez-Valero, Lisa R Fodero, Anthony R White, Colin J Barrow, David H Smal. Acetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with beta-amyloid peptides. Brain research. vol 965. issue 1-2. 2003-05-01. PMID:12591148. |
the cellular origin of the acetylcholinesterase (ache) associated with amyloid plaques in the alzheimer's disease (ad) brain is unknown. |
2003-05-01 |
2023-08-12 |
mouse |